目的通過(guò)觀察蜈蚣提取物(CSE)對(duì)人肝癌細(xì)胞Hep G2及裸鼠肝癌原位移植瘤的影響,探討其抗肝癌的機(jī)制。方法 Hep G2細(xì)胞分為CSE₂₅₀(250μg/m L)處理組、CSE₅₀₀(500μg/m L)處理組、5-FU(5-氟尿嘧啶)處理組和對(duì)照組,采用酶解丙酮沉淀法分離純化CSE并作用于人肝癌細(xì)胞HepG2,CCK8法檢測(cè)細(xì)胞增殖抑制,流式細(xì)胞術(shù)檢測(cè)細(xì)胞周期變化。Western blot檢測(cè)CSE處理后HepG2細(xì)胞信號(hào)傳導(dǎo)與轉(zhuǎn)錄激活因子3(STAT3)信號(hào)通路相關(guān)蛋白表達(dá)變化。制備人肝癌細(xì)胞裸鼠原位移植瘤模型,隨機(jī)分為模型組、5-FU組、CSE₁₀組[10mg/(kg·d)]和CSE₅₀組[50mg/(kg·d)],每組12只,觀察裸鼠原位移植瘤瘤體體積及質(zhì)量變化,并檢測(cè)瘤體p-STAT3、p38絲裂原激活的蛋白激酶(p38MAPK)蛋白表達(dá)水平。取模型組及CSE₅₀組裸鼠肝原位移植瘤組織,采用蛋白酪氨酸激酶(PTKs)芯片技術(shù)檢測(cè)并對(duì)差異蛋白進(jìn)行GO及KEGG分析。結(jié)...

【文章頁(yè)數(shù)】：13 頁(yè)

【文章目錄】：
1 Introduction
2 Materials and Methods
    2.1 Animals and cell lines
    2.2 Drug preparation
    2.3 In vitro test indicator
        2.3.1 Grouping and cell proliferation inhibition rate measurement
        2.3.2 Cell cycle detection
        2.3.3 Detection of STAT3 pathway protein expression
    2.4 Animal model preparation and group drug administration
        2.4.1 Preparation of nude mice with orthotopic livertumors
        2.4.2 Animal grouping and intervention
    2.5 In vivo test indicators
        2.5.1 Tumor suppression rate
        2.5.2 Protein tyrosine kinase(PTK)chip assay
        2.5.3 Gene Ontology(GO)and Kyoto Encyclopediaof Genes and Genomes(KEGG)enrichment analysis
    2.6 Statistical analysis
3 Results
    3.1 Inhibitory effects of CSE on human liver cancer HepG2 cell proliferation
    3.2 Effects of CSE on HepG2 cell cycle
    3.3 STAT3 pathway protein expression
    3.4 Effects of CSE on the mass and volume of livercancer orthotopic transplantation tumor,as well as the protein level of STAT3 signaling pathway
    3.5 PTK antibody chip screening results
    3.6 Prediction of differential protein’s funtion by GO and KEGG analysis using Metascape
4 Discussion



本文編號(hào)：3972292